ER/HER2/Ki67 Breast Cancer Subtypes as Predictive Factors for Response to Adjuvant Dose-dense Therapy, and Basal Subtypes of Double-negative Breast Cancer as Prognostic Factors in Intergroup Trial C9741
18 Years
N/A
Female
Breast Cancer
Trial Information
ER/HER2/Ki67 Breast Cancer Subtypes as Predictive Factors for Response to Adjuvant Dose-dense Therapy, and Basal Subtypes of Double-negative Breast Cancer as Prognostic Factors in Intergroup Trial C9741
OBJECTIVES:
Primary
- To identify biomarkers that can be used to individually tailor the use of adjuvant
dose-dense therapy in women with stage II or IIIA breast cancer.
Secondary
- To identify groups of patients who have a poor prognosis despite adjuvant chemotherapy
and who should be prospectively targeted for new approaches to adjuvant treatment.
OUTLINE: This is a multicenter study.
Tissue samples are collected from patients. Tissue samples are analyzed by
immunohistochemistry (Ki67, CK5/6, EGFR, ER) and fluorescence in situ hybridization (FISH).
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of node-positive breast cancer
- Stage II-IIIA disease
- Underwent adjuvant chemotherapy on trial CLB-9741 or CLB-9344
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Menopausal status not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Disease-free survival
Safety Issue:
No
Principal Investigator
Matthew J. Ellis, MD, PhD, FRCP
Investigator Role:
Study Chair
Investigator Affiliation:
Washington University Siteman Cancer Center
Authority:
United States: Federal Government
Study ID:
CDR0000589237
NCT ID:
NCT00897026
Start Date:
July 2008
Completion Date:
Related Keywords:
- Breast Cancer
- stage II breast cancer
- stage IIIA breast cancer
- Breast Neoplasms
Name | Location |
|---|
